Skip to main content
Fig. 4 | Breast Cancer Research

Fig. 4

From: Evaluation of tumour heterogeneity by 18F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment

Fig. 4

Representative imaging of patients with at least one 18F-FES-negative lesion. A Only 18F-FES-negative lesions (Fig. 2, #43). This 50-year-old woman had 4 18F-FDG-positive lesions in her chest wall and lymph nodes, but all were negative on 18F-FES PET. She was on palbociclib combined with letrozole as first-line treatment for 2.3 months until progression occurred. B Presence of 18F-FES-positive and 18F-FES-negative lesions (Fig. 2, #49). This 53-year-old woman had innumerable 18F-FDG-positive and 18F-FES-positive lesions in the pleura, lung, lymph nodes, and bone, but the left chest wall metastasis showed outstanding uptake of 18F-FDG but not of 18F-FES. She was on palbociclib combined with fulvestrant as third-line treatment for 5.6 months until progression occurred

Back to article page